Page 84 - GPD-4-2

Gene & Protein in Disease Alport syndrome: Genetics, variability, and management

doi: 10.53347/rid-55939 doi: 10.1007/S00467-021-05040-9
11. Jeanne M, Labelle-Dumais C, Jorgensen J, et al. COL4A2 22. Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA.
Mutations Impair COL4A1 and COL4A2 secretion and COL4A3/COL4A4 mutations and features in individuals
cause hemorrhagic stroke. Am J Hum Genet. 2012;90(1):91. with autosomal recessive alport syndrome. J Am Soc Nephrol.
2013;24(12):1945-1954.
doi: 10.1016/J.AJHG.2011.11.022
doi: 10.1681/ASN.2012100985
12. Heidet L, Gubler MC. The renal lesions of Alport syndrome.
J Am Soc Nephrol. 2009;20(6):1210-1215. 23. García-Aznar JM, De la Higuera L, Besada Cerecedo L, et al.
New insights into renal failure in a cohort of 317 patients
doi: 10.1681/ASN.2008090984
with autosomal dominant forms of alport syndrome: Report
13. Kang E, Park BH, Lee H, et al. A comprehensive review of two novel heterozygous mutations in COL4A3. J Clin
of Alport syndrome: Definition, pathophysiology, clinical Med. 2022;11(16):4883.
manifestations, and diagnostic considerations. Korean J
Nephrol. 2024. doi: 10.3390/JCM11164883/S1
24. Marcocci E, Uliana V, Bruttini M, et al. Autosomal dominant
doi: 10.23876/J.KRCP.24.065
Alport syndrome: Molecular analysis of the COL4A4
14. Jais JP, Knebelmann B, Giatras I, et al. X-linked alport gene and clinical outcome. Nephrol Dial Transplant.
syndrome. J Am Soc Nephrol. 2000;11(4):649-657. 2009;24(5):1464-1471.
doi: 10.1681/ASN.V114649 doi: 10.1093/NDT/GFN681
15. Shaw EA, Colville D, Wang YY, et al. Characterization 25. Savige J, Renieri A, Ars E, et al. Digenic alport syndrome.
of the peripheral retinopathy in X-linked and autosomal Clin J Am Soc Nephrol. 2022;17(11):1697-1706.
recessive Alport syndrome. Nephrol Dial Transplant.
2007;22(1):104-108. doi: 10.2215/CJN.03120322
26. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome:
doi: 10.1093/NDT/GFL607
A unified classification of genetic disorders of collagen IV
16. Christopher A, Kaur R, Kaur G, Kaur A, Gupta V, α345: A position paper of the Alport Syndrome Classification
Bansal P. MicroRNA therapeutics: Discovering novel targets Working Group. Kidney Int. 2018;93(5):1045-1051.
and developing specific therapy. Perspect Clin Res. 2016;7(2):68.
doi: 10.1016/J.KINT.2017.12.018
doi: 10.4103/2229-3485.179431
27. Mencarelli MA, Heidet L, Storey H, et al. Evidence of
17. Nozu K, Minamikawa S, Yamada S, et al. Characterization digenic inheritance in Alport syndrome. J Med Genet.
of contiguous gene deletions in COL4A6 and COL4A5 in 2015;52(3):163-174.
Alport syndrome-diffuse leiomyomatosis. J Hum Genet.
2017;62(7):733-735. doi: 10.1136/JMEDGENET-2014-102822
28. Yamamura T, Nozu K, Minamikawa S, et al. Comparison
doi: 10.1038/JHG.2017.28
between conventional and comprehensive sequencing
18. Uliana V, Marcocci E, Mucciolo M, et al. Alport syndrome approaches for genetic diagnosis of Alport syndrome. Mol
and leiomyomatosis: The first deletion extending beyond Genet Genomic Med. 2019;7(9):e883.
COL4A6 intron 2. Pediatr Nephrol. 2011;26(5):717-724.
doi: 10.1002/MGG3.883
doi: 10.1007/S00467-010-1693-9
29. Furlano M, Arlandis R, Del Prado Venegas M, et al. MYH9
19. Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, Associated nephropathy. Nefrología (English Edition).
pathological and molecular features of glomerular 2019;39(2):133-140.
basement membrane nephropathy caused by COL4A3 or
COL4A4 mutations: A systematic review. Clin Kidney J. doi: 10.1016/J.NEFROE.2018.08.006
2020;13(6):1025. 30. Oh T, Seo HJ, Lee KT, et al. MYH9 nephropathy. Kidney Res
Clin Pract. 2014;34(1):53.
doi: 10.1093/CKJ/SFZ176
doi: 10.1016/J.KRCP.2014.09.003
20. Lee JM, Nozu K, Choi DE, Kang HG, Ha IS, Cheong HII.
Features of autosomal recessive alport syndrome: 31. Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY.
A systematic review. J Clin Med. 2019;8(2):178. Thin basement membrane nephropathy. Kidney Int.
2003;64(4):1169-1178.
doi: 10.3390/JCM8020178
doi: 10.1046/j.1523-1755.2003.00234.x
21. Zhang Y, Böckhaus J, Wang F, et al. Genotype-phenotype
correlations and nephroprotective effects of RAAS inhibition 32. Gross O, Tönshoff B, Weber LT, et al. A multicenter,
in patients with autosomal recessive Alport syndrome. randomized, placebo-controlled, double-blind phase 3 trial
Pediatr Nephrol. 2021;36(9):2719-2730. with open-arm comparison indicates safety and efficacy of

Volume 4 Issue 2 (2025) 10 doi: 10.36922/gpd.7656